Alnylam Pharmaceuticals (ALNY) Earnings Date, Estimates & Call Transcripts → The Gold Grab of the Century (From Colonial Metals) (Ad) Free alny Stock Alerts $143.31 -0.40 (-0.28%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 2Before Market OpensConfirmedActual EPS (Feb. 15) -$1.10 Beat By $0.10 Consensus EPS (Feb. 15) -$1.20 Read Call TranscriptListen to Call Get Alnylam Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for ALNY and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALNY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALNY Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. Alnylam Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244($1.26)($0.70)($1.02) Q2 20244($1.38)($0.76)($1.09) Q3 20244($1.05)($0.76)($0.93) Q4 20244($1.12)($0.70)($0.88) FY 202416($4.81)($2.92)($3.92) Q1 20251($0.57)($0.57)($0.57) Q2 20251($0.55)($0.55)($0.55) Q3 20251($0.51)($0.51)($0.51) Q4 20251($0.36)($0.36)($0.36) FY 20254($1.99)($1.99)($1.99) Q1 20261$0.32$0.32$0.32 ALNY Earnings Date and InformationAlnylam Pharmaceuticals last issued its quarterly earnings results on February 15th, 2024. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. Its quarterly revenue was up 31.2% on a year-over-year basis. Alnylam Pharmaceuticals has generated ($3.56) earnings per share over the last year (($3.56) diluted earnings per share). Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($4.46) to ($2.16) per share. Alnylam Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, May 2nd, 2024. Alnylam Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call.. Read More Alnylam Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Confirmed)------- 2/15/2024Q4 2023($1.20)($1.10)+$0.10($1.10)$439.38 million$439.72 million 11/2/2023Q3 2023($1.61)$1.15+$2.76$1.15$406.14 million$750.53 million8/3/2023Q2 2023($1.72)($2.21)($0.49)($2.21)$331.73 million$318.75 million5/4/2023Q1 2023($1.97)($1.40)+$0.57($1.40)$312.53 million$319.29 million 2/23/2023Q4 2022($2.13)($1.68)+$0.45($1.68)$312.45 million$335.04 million 10/27/2022Q3 2022($1.86)($3.32)($1.46)($3.32)$291.81 million$264.31 million Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/28/2022Q2 2022($1.62)($2.29)($0.67)($2.29)$256.06 million$224.80 million 4/28/2022Q1 2022($1.93)($2.00)($0.07)($2.00)$242.82 million$186.90 million 2/10/2022Q4 2021($1.47)($2.16)($0.69)($2.16)$233.62 million$258.10 million 10/27/2021Q3 2021($1.51)($1.72)($0.21)($1.72)$218.69 million$187.63 million 8/2/2021Q2 2021($1.61)($1.61)-($1.61)$193.66 million$220.55 million 4/28/2021Q1 2021($1.75)($1.71)+$0.04($1.71)$176.93 million$177.57 million Alnylam Pharmaceuticals Earnings - Frequently Asked Questions When is Alnylam Pharmaceuticals's earnings date? Alnylam Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, May 2nd, 2024. Learn more on ALNY's earnings history. Did Alnylam Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported ($1.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.20) by $0.10. Learn more on analysts' earnings estimate vs. ALNY's actual earnings. How can I listen to Alnylam Pharmaceuticals's earnings conference call? The conference call for Alnylam Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Alnylam Pharmaceuticals's conference call transcript? The conference call transcript for Alnylam Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded annual revenue of $1.83 billion. How much profit does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded net income of -$440.24 million. ALNY has generated -$3.56 earnings per share over the last four quarters. What is Alnylam Pharmaceuticals's EPS forecast for next year? Alnylam Pharmaceuticals's earnings are expected to grow from ($4.46) per share to ($2.16) per share in the next year. More Earnings Resources from MarketBeat Related Companies: BioMarin Pharmaceutical Earnings Date Royalty Pharma Earnings Date United Therapeutics Earnings Date Ionis Pharmaceuticals Earnings Date Madrigal Pharmaceuticals Earnings Date Genmab A/S Earnings Date Teva Pharmaceutical Industries Earnings Date Viatris Earnings Date BeiGene Earnings Date Karuna Therapeutics Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:ALNY) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.